Evidence map›Paper›PMID 40087816›Full record

ArticleChemical biology & drug design2025

The Nature of Nanodisc Lipids Influences Fragment-Based Drug Discovery Results.

Tim G J Knetsch, Henri van Son, Masakazu Kobayashi, Marcellus Ubbink

Abstract read
In one paragraph

Article in Chemical biology & drug design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tim G J KnetschLeiden Institute of Chemistry, Leiden University, Leiden, the Netherlands.ORCID https://orcid.org/0000-0002-9575-5195
Henri van SonZoBio B.V., Leiden, the Netherlands.ORCID https://orcid.org/0000-0001-6206-2061
Masakazu KobayashiZoBio B.V., Leiden, the Netherlands.
Marcellus UbbinkLeiden Institute of Chemistry, Leiden University, Leiden, the Netherlands.ORCID https://orcid.org/0000-0002-2615-6914

Funding

Batavia Biosciences B.VNederlandse Organisatie voor Wetenschappelijk OnderzoekZoBio B.V
6 · The paper itself

Abstract

Membrane proteins (MPs) are important yet challenging targets for drug discovery. MPs can be reconstituted in protein-lipid Nanodiscs (NDs), which resemble the native membrane environment. Drug-membrane interactions can affect the apparent binding stoichiometry and affinity, as well as the kinetics of ligands for a particular target, which is important for the extrapolation to pharmacokinetic studies. To investigate the role of the membrane, we have applied fragment-based drug discovery (FBDD) methods to cytochrome P450 3A4 (CYP3A4), reconstituted in NDs composed of different phosphocholine lipids: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), or 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DPhPC). Surface plasmon resonance screening of fragments and marketed drugs revealed extensive binding to the empty ND, correlating with analyte hydrophobicity, and the binding was critically dependent on ND lipid composition. POPC NDs showed much higher binding of fragments than DMPC and DPhPC NDs, resulting in a lower hit rate for CYP3A4 in POPC NDs, which demonstrated that the choice of the ND lipid is crucial to the outcome of a screen. The number of binders that were rejected based on atypical binding kinetics was lower for monomeric CYP3A4 in NDs than for non-native oligomeric CYP3A4 without the ND. Several fragments were exclusively identified as hits for CYP3A4 in the presence of the ND membrane. It is concluded that the nature of the ND is a critical factor for fragment screening of membrane proteins.

Indexed as

Cytochrome P-450 CYP3ADrug DiscoveryNanostructuresPhosphatidylcholines1,2-DipalmitoylphosphatidylcholineDimyristoylphosphatidylcholineHumansProtein BindingSurface Plasmon Resonance1,2-Dipalmitoylphosphatidylcholine1,2-diphytanoylphosphatidylcholine1-palmitoyl-2-oleoylphosphatidylcholineCytochrome P-450 CYP3ADimyristoylphosphatidylcholinePhosphatidylcholinescytochrome P450drug‐membrane interactionsfragment‐based drug discoverynanodiscssurface plasmon resonance

Identifiers

PMID40087816
PMCPMC11909325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.